Free public records show Hangzhou Highlightll Pharmaceutical Co., Ltd in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Hangzhou Highlightll Pharmaceutical Co., Ltd or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
7 active studies led by Hangzhou Highlightll Pharmaceutical Co., Ltd, of 14 in all
Source: ClinicalTrials.gov, Studies with Hangzhou Highlightll Pharmaceutical Co., Ltd (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies Hangzhou Highlightll Pharmaceutical Co., Ltd leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Hangzhou Highlightll Pharmaceutical Co., Ltd or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Hangzhou Highlightll Pharmaceutical Co., Ltd: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Hangzhou Highlightll Pharmaceutical Co., Ltd is in.
Stories on the topics Hangzhou Highlightll Pharmaceutical Co., Ltd works in.
Collagen powders promise younger skin and easier joints. A 2025 review of 23 trials found the benefits…
Read
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
Plastic surgeons performed more than 19.1 million non-surgical aesthetic procedures in 2023. Hair removal and…
ReadSearch all reports for Hangzhou Highlightll Pharmaceutical Co., Ltd All companies